N-(二甲胺基-4-甲基香豆素基)顺丁烯二酰亚胺 | 55145-14-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 中文名称: N-(二甲胺基-4-甲基香豆素基)顺丁烯二酰亚胺
• 中文别名: N-(7-二甲氨基-4-甲基-3-香豆素基)马来酰亚胺；N-(二甲胺基-4-甲基香豆素基)顺丁烯二酰亚胺〔DACM〕
• 英文名称: 1-(7-Dimethylamino-4-methyl-3-cumarinyl)-maleimid
• 英文别名: 1H-Pyrrole-2,5-dione, 1-[7-(dimethylamino)-4-methyl-2-oxo-2H-1-benzopyran-3-yl]-；1-[7-(dimethylamino)-4-methyl-2-oxochromen-3-yl]pyrrole-2,5-dione
• CAS: 55145-14-7
• 化学式: C₁₆H₁₄N₂O₄
• 分子量: 298.298
• InChiKey: ADEORFBTPGKHRP-UHFFFAOYSA-N

物化性质

• 熔点：
  218-220 °C(lit.)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）
• 稳定性/保质期：

  如果按照规格使用和储存，则不会分解，未有已知危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  66.9
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R37/38
• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  N-(二甲胺基-4-甲基香豆素基)顺丁烯二酰亚胺 、 2-[2-[2-[(2-Oxo-1,3,2lambda5-dioxaphospholan-2-yl)oxy]ethoxy]ethoxy]-1,3,2lambda5-dioxaphospholane 2-oxide 在 吩噻嗪 作用下， 以68 %的产率得到
  参考文献：
  名称：

  ホスホリルコリン基又はその類似基含有重合性化合物、化合物の製造方法及び重合体、並びに化合物を用いた樹脂組成物

  摘要：

  【課題】優れた生体適合性を有し、熱や活性エネルギー線に対する重合性や硬化性が高く、ホスホリルコリン基又はその類似基を有する重合性化合物、それらの製造方法及びそれらを用いた重合体、硬化性樹脂組成物等を提供する。【解決手段】本発明の化合物は、分子内に不飽和基２個以上とホスホリルコリン基及び／又はホスホリルコリン類似基１個以上を有する重合性化合物、及び分子内に不飽和基１個とホスホリルコリン基及び／又はホスホリルコリン類似基２個以上を有する重合性化合物である。【選択図】なし

  公开号：

  JP2023026106A
• 作为产物：
  描述：

  3-amino-7-dimethylamino-4-methyl-chromen-2-one 、 乙酸酐 生成 N-(二甲胺基-4-甲基香豆素基)顺丁烯二酰亚胺
  参考文献：
  名称：

  CORRIE, JOHN E. T., J. CHEM. SOC. PERKIN TRANS. PT 1,(1990) N, C. 2151-2152

  摘要：

  DOI：

文献信息

• Compounds for binding to ERalpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof
  申请人：Prossnitz Eric R.

  公开号：US20080167334A1

  公开（公告）日：2008-07-10

  The current invention is in the field of molecular biology/pharmacology and provides compounds which modulate the effects of GPR30 as well as the classical estrogen receptors alpha and beta (ERα and ERβ). These compounds may function as agonists and/or antagonists of one or more of the disclosed estrogen receptors. Diseases which are mediated through one or more of these receptors include cancer (particularly breast, reproductive and other hormone-dependent cancers, leukemia, colon cancer, prostate cancer), reproductive (genito-urological) including endometritis, prostatitis, polycystic ovarian syndrome, bladder control, hormone-related disorders, hearing disorders, cardiovascular conditions including hot flashes and profuse sweating, hypertension, stroke, obesity, osteoporosis, hematologic diseases, vascular diseases or conditions such as venous thrombosis, atherosclerosis, among numerous others and disorders of the central and peripheral nervous system, including depression, insomnia, anxiety, multiple sclerosis, neuropathy, neurodegenerative disorders such as Parkinson's disease and Alzheimer's disease, as well as inflammatory bowel disease, Crohn's disease, coeliac (celiac) disease and related disorders of the intestine. A contraceptive indication to prevent or reduce the likelihood of pregnancy after intercourse is a further aspect of the present invention.

  当前的发明涉及分子生物学/药理学领域，并提供调节GPR30以及经典雌激素受体α和β（ERα和ERβ）效应的化合物。这些化合物可能作为抗原或/和拮抗剂作用于所披露的一个或多个雌激素受体。通过这些受体中的一个或多个介导的疾病包括癌症（特别是乳腺、生殖和其他激素依赖性癌症、白血病、结肠癌、前列腺癌）、生殖（泌尿生殖系统）包括子宫内膜炎、前列腺炎、多囊卵巢综合征、膀胱控制、激素相关疾病、听力障碍、心血管疾病包括潮热和大量出汗、高血压、中风、肥胖、骨质疏松症、血液学疾病、血管疾病或情况如静脉血栓形成、动脉粥样硬化等，以及中枢和外周神经系统的疾病，包括抑郁症、失眠、焦虑、多发性硬化、神经病、帕金森病和阿尔茨海默病等神经退行性疾病，以及炎症性肠病、克罗恩病、乳糜泻病和相关肠道疾病。避孕指示以预防或减少性交后怀孕的可能性是本发明的另一个方面。
• Nucleic acid labeling compounds
  申请人：McGall H. Glenn

  公开号：US20050003496A1

  公开（公告）日：2005-01-06

  Nucleic acid labeling compounds containing heterocyclic derivatives are disclosed. Methods for making such heterocyclic compounds are also disclosed. The labeling compounds are suitable for enzymatic attachment to a nucleic acid, either terminally or internally, to provide a mechanism of nucleic acid detection.

  揭示了含有杂环衍生物的核酸标记化合物。还公开了制备这种杂环化合物的方法。这些标记化合物适用于通过酶的附着，无论是末端还是内部，提供核酸检测的机制。
• REAGENTS FOR LABELLING NUCLEIC ACIDS AND USES THEREOF
  申请人：Mouritzen Peter

  公开号：US20090023594A1

  公开（公告）日：2009-01-22

  The present invention relates to labelling kits containing novel non-natural nucleotide monomers and to methods of making and using such compounds. The invention further relates to a method of detecting the presence of a nucleic acid, e.g., RNA, of interest in a sample, the method having the following steps: providing the sample; ligating a nucleic acid of interest with a labelling reagent according to the instant invention; providing a nucleic acid array having probes directed to the nucleic acid of interest; hybridizing the labelled nucleic acid fragments to said nucleic acid array; and determining the extent of hybridization to said probes to determine the presence of the nucleic acid of interest.

  本发明涉及包含新型非自然核苷酸单体的标记试剂盒以及制备和使用这些化合物的方法。本发明还涉及一种检测样品中感兴趣的核酸（例如RNA）存在的方法，该方法包括以下步骤：提供样品；使用本发明的标记试剂将感兴趣的核酸连接起来；提供具有针对感兴趣的核酸的探针的核酸阵列；将标记的核酸片段杂交到该核酸阵列上；并确定杂交到探针的程度以确定感兴趣的核酸是否存在。
• NUCLEIC ACID LABELING COMPOUNDS
  申请人：——

  公开号：US20010018514A1

  公开（公告）日：2001-08-30

  Nucleic acid labeling compounds containing heterocyclic derivatives are disclosed. The heterocyclic derivative containing compounds are synthesized by condensing a heterocyclic derivative with a cyclic group (e.g. a ribofuranose derivative). The labeling compounds are suitable for enzymatic attachment to a nucleic acid, either terminally or internally, to provide a mechanism of nucleic acid detection.

  本发明揭示了含有杂环衍生物的核酸标记化合物。这些含有杂环衍生物的化合物是通过将杂环衍生物与环状基团（例如核糖呋喃衍生物）缩合而合成的。这些标记化合物适用于酶促连接到核酸上，无论是末端或内部，以提供核酸检测的机制。
• Hydrophobically-modified protein compositions and methods
  申请人：Pepinsky Blake R.

  公开号：US20050119181A1

  公开（公告）日：2005-06-02

  Hydrophobically-modified proteins and methods of making them are described. A hydrophobic moiety is attached to a surface amino acid residue of the protein. The hydrophobic moiety can be a lipid or a peptide. Alternatively, the protein can be derivatized by a wide variety of chemical reactions that append a hydrophobic structure to the protein. The preferred protein is of mammalian origin and is selected from the group consisting of Sonic, Indian, and Desert hedgehog. The hydrophobic moiety is used as a convenient tether to which may be attached a vesicle such as a cell membrane, liposome, or micelle.

  描述了一种水疏性修饰蛋白质及其制备方法。将一种疏水基团附加到蛋白质的表面氨基酸残基上。该疏水基团可以是脂质或肽。或者，可以通过各种化学反应使蛋白质衍生出一个疏水结构。优选的蛋白质是哺乳动物来源的，并从Sonic，Indian和Desert hedgehog组中选择。该疏水基团可用作方便的系链，可附着细胞膜、脂质体或微胶束等载体。

表征谱图